PURPOSE: To report the first occurrence of successful ovarian stimulation, oocyte retrieval and oocyte cryopreservation for fertility preservation in an adolescent with severe sickle cell disease scheduled to undergo a hematopoietic stem cell transplant METHODS: Case report. RESULTS: A 19 year old female with severe sickle cell disease presented for fertility preservation counseling prior to hematopoietic stem cell transplantation. She ultimately underwent ovarian stimulation using a minimal stimulation GnRH antagonist protocol resulting in the successful banking of oocytes prior to transplant. The unique hazards associated with ovarian stimulation in patients with sickle cell disease, such as thrombosis and vaso-occlusive events, are discussed and the methods undertaken to minimize these risks are described. CONCLUSIONS: Controlled ovarian hyperstimulation and oocyte banking for fertility preservation is feasible in young women with sickle cell disease requiring hematopoietic stem cell transplant and deserves further investigation. Given the elevated risk of thrombosis and predisposition to painful vaso-occlusive events, controlled ovarian hyperstimulation in patients with sickle cell disease is not straightforward and requires a multi-disciplinary team approach to adequately address and minimize the risks in this unique patient population.
PURPOSE: To report the first occurrence of successful ovarian stimulation, oocyte retrieval and oocyte cryopreservation for fertility preservation in an adolescent with severe sickle cell disease scheduled to undergo a hematopoietic stem cell transplant METHODS: Case report. RESULTS: A 19 year old female with severe sickle cell disease presented for fertility preservation counseling prior to hematopoietic stem cell transplantation. She ultimately underwent ovarian stimulation using a minimal stimulation GnRH antagonist protocol resulting in the successful banking of oocytes prior to transplant. The unique hazards associated with ovarian stimulation in patients with sickle cell disease, such as thrombosis and vaso-occlusive events, are discussed and the methods undertaken to minimize these risks are described. CONCLUSIONS: Controlled ovarian hyperstimulation and oocyte banking for fertility preservation is feasible in young women with sickle cell disease requiring hematopoietic stem cell transplant and deserves further investigation. Given the elevated risk of thrombosis and predisposition to painful vaso-occlusive events, controlled ovarian hyperstimulation in patients with sickle cell disease is not straightforward and requires a multi-disciplinary team approach to adequately address and minimize the risks in this unique patient population.
Authors: M Matsumoto; O Shinohara; H Ishiguro; T Shimizu; K Hattori; M Ichikawa; H Yabe; C Kubota; M Yabe; S Kato Journal: Arch Dis Child Date: 1999-05 Impact factor: 3.791
Authors: Elpis Vlachopapadopoulou; V Kitra; J Peristeri; E Goussetis; F Karachaliou; D Petropoulos; A Fotinou; S Michalacos; S Graphakos Journal: J Pediatr Endocrinol Metab Date: 2005-05 Impact factor: 1.634
Authors: Stephanie J Lee; Leslie R Schover; Ann H Partridge; Pasquale Patrizio; W Hamish Wallace; Karen Hagerty; Lindsay N Beck; Lawrence V Brennan; Kutluk Oktay Journal: J Clin Oncol Date: 2006-05-01 Impact factor: 44.544
Authors: A D Schimmer; M Quatermain; K Imrie; V Ali; J McCrae; A K Stewart; M Crump; C Derzko; A Keating Journal: J Clin Oncol Date: 1998-07 Impact factor: 44.544
Authors: Diane Chen; Lia A Bernardi; Mary Ellen Pavone; Eve C Feinberg; Molly B Moravek Journal: J Assist Reprod Genet Date: 2018-08-22 Impact factor: 3.412
Authors: Robert Sheppard Nickel; Jacqueline Y Maher; Michael H Hsieh; Meghan F Davis; Matthew M Hsieh; Lydia H Pecker Journal: J Clin Med Date: 2022-04-21 Impact factor: 4.964
Authors: Mark C Walters; Laura M De Castro; Keith M Sullivan; Lakshmanan Krishnamurti; Naynesh Kamani; Christopher Bredeson; Donna Neuberg; Kathryn L Hassell; Stephanie Farnia; Andrew Campbell; Effie Petersdorf Journal: Biol Blood Marrow Transplant Date: 2015-10-21 Impact factor: 5.742